171 related articles for article (PubMed ID: 8222482)
21. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.
MacPhee IA; Spreafico S; Bewick M; Davis C; Eastwood JB; Johnston A; Lee T; Holt DW
Kidney Int; 2000 Mar; 57(3):1164-8. PubMed ID: 10720968
[TBL] [Abstract][Full Text] [Related]
22. Appropriate drug dosing in patients receiving peritoneal dialysis.
Hirata S; Kadowaki D
Contrib Nephrol; 2012; 177():30-37. PubMed ID: 22613912
[TBL] [Abstract][Full Text] [Related]
23. Beta 2-microglobulin elimination in end-stage renal disease patients on renal replacement therapy.
Stefanović V; Kostić S; Djordjević V; Mitić M; Bogicević M
Perit Dial Int; 1993; 13 Suppl 2():S520-2. PubMed ID: 8399654
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of cefotaxime in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis.
Hasegawa H; Imada A; Horiuchi A; Nishii Y; Fukushima M; Kurokawa E
J Antimicrob Chemother; 1984 Sep; 14 Suppl B():135-42. PubMed ID: 6094432
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of esmolol and ASL-8123 in renal failure.
Flaherty JF; Wong B; La Follette G; Warnock DG; Hulse JD; Gambertoglio JG
Clin Pharmacol Ther; 1989 Mar; 45(3):321-7. PubMed ID: 2563962
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.
Albin H; Ragnaud JM; Demotes-Mainard F; Vinçon G; Couzineau M; Wone C
Eur J Clin Pharmacol; 1986; 31(4):479-83. PubMed ID: 3816928
[TBL] [Abstract][Full Text] [Related]
27. Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis (CAPD).
Walker SE; Paton TW; Churchill DN; Ojo B; Manuel MA; Wright N
Perit Dial Int; 1989; 9(1):51-5. PubMed ID: 2488182
[TBL] [Abstract][Full Text] [Related]
28. [Role of continuous ambulatory peritoneal dialysis (CAPD) in a program for the treatment of chronic renal insufficiency. Problems posed by transfer of CAPD to transplantation or hemodialysis].
Canaud B; Mion C
Nephrologie; 1995; 16(1):129-35. PubMed ID: 7700413
[TBL] [Abstract][Full Text] [Related]
29. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.
Heimbürger O; Stenvinkel P; Berglund L; Tranoeus A; Lindholm B
Nephron; 1996; 72(2):135-44. PubMed ID: 8684516
[TBL] [Abstract][Full Text] [Related]
30. [Pharmacokinetics of cefotiam in patients undergoing continuous ambulatory peritoneal dialysis].
Itagaki N; Hasegawa H; Tsujino M; Takahashi K; Yamamoto Y; Imada A; Horiuchi A
Jpn J Antibiot; 1988 Apr; 41(4):405-8. PubMed ID: 3165474
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.
Low CL; Gopalakrishna K; Lye WC
J Am Soc Nephrol; 2000 Jun; 11(6):1117-1121. PubMed ID: 10820176
[TBL] [Abstract][Full Text] [Related]
32. Vancomycin pharmacokinetics in continuous ambulatory peritoneal dialysis patients with peritonitis.
Harford AM; Sica DA; Tartaglione T; Polk RE; Dalton HP; Poynor W
Nephron; 1986; 43(3):217-22. PubMed ID: 3724930
[TBL] [Abstract][Full Text] [Related]
33. Evidence for preservation of cortical bone mineral density in patients on continuous ambulatory peritoneal dialysis.
Mottet JJ; Horber FF; Casez JP; Descoeudres C; Jaeger P
J Bone Miner Res; 1996 Jan; 11(1):96-104. PubMed ID: 8770702
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of clindamycin in the plasma and dialysate after intraperitoneal administration of clindamycin phosphoester to patients on continuous ambulatory peritoneal dialysis: an open-label, prospective, single-dose, two-institution study.
Chang MJ; Namgung H; Choi HD; Song YR; Kim SG; Oh JM; Shin WG
Basic Clin Pharmacol Toxicol; 2012 Jun; 110(6):504-9. PubMed ID: 22151828
[TBL] [Abstract][Full Text] [Related]
35. The effects of continuous ambulatory peritoneal dialysis and hemodialysis on serum pepsinogen concentrations in patients with chronic renal failure.
Aydemir S; Borazan A; Acikgoz S; Ustundag Y; Yilmaz A
Tohoku J Exp Med; 2005 Mar; 205(3):263-8. PubMed ID: 15718818
[TBL] [Abstract][Full Text] [Related]
36. Urea kinetics evaluation of hemodialysis and CAPD patients.
Acchiardo SR; Kraus AP; LaHatte G; Kaufman PA; Adkins D; Moore LW
Adv Perit Dial; 1992; 8():55-8. PubMed ID: 1361852
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis.
Benziger DP; Pertel PE; Donovan J; Yankelev S; Schwab RJ; Swan SK; Cannon C
Clin Nephrol; 2011 Jan; 75(1):63-9. PubMed ID: 21176752
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic comparison of flurbiprofen in end-stage renal disease subjects and subjects with normal renal function.
Cefali EA; Poynor WJ; Sica D; Cox S
J Clin Pharmacol; 1991 Sep; 31(9):808-14. PubMed ID: 1804864
[TBL] [Abstract][Full Text] [Related]
39. Teicoplanin pharmacokinetics and bioavailability during peritoneal dialysis.
Brouard RJ; Kapusnik JE; Gambertoglio JG; Schoenfeld PY; Sachdeva M; Freel K; Tozer TN
Clin Pharmacol Ther; 1989 Jun; 45(6):674-81. PubMed ID: 2525081
[TBL] [Abstract][Full Text] [Related]
40. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.
Keller E; Reetze P; Schollmeyer P
Clin Pharmacokinet; 1990 Feb; 18(2):104-17. PubMed ID: 2180611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
